Figure 3.
Meta-analysis of Artesunate + Amodiaquine (AS+AQ) Versus Arthemeter-Lumefantrine (AL) in Middle Africa
All studies that satisfied the inclusion criteria and were conducted in Middle Africa were included in this analysis. The outcome measure of interest (day 28 parasitological failure) is not clinically desirable; therefore, the right side of the graph favours Arthemeter-Lumefantrine. The absence of inconsistencies is striking